Apollo vaccine triggers broad rhinovirus immunity in Phase 1
UK biotech Apollo Therapeutics has reported early Phase 1 data showing that one dose of its experimental rhinovirus vaccine, APL-10456, induced immune responses recognizing all three rhinovirus species in healthy adults.
Why it matters: Rhinovirus is a major trigger of chronic obstructive pulmonary disease (COPD) exacerbations, but its roughly 180 strains have frustrated attempts to develop a broadly protective vaccine. There are currently no approved vaccines or targeted treatments for the virus.
By the numbers: The randomized, double-blind and placebo-controlled Phase 1 trial enrolled 144 healthy volunteers. Part A tested three single-dose levels in adults ages 18–54. Part B is evaluating two doses in people ages 55 and older.
- Apollo said the most common adverse events in Part A were mild-to-moderate injection-site reactions. No serious adverse events were reported.
- Results from Part B are expected in the fourth quarter of 2026.
How it works: Most antiviral antibodies recognize exposed parts of a virus that differ between rhinovirus strains. APL-10456 instead combines a conserved recombinant protein antigen with adjuvants intended to produce a Th1-polarized immune response — a type of immune reaction that activates virus-fighting T cells. The aim is to generate CD4+ and CD8+ T cells that recognize multiple rhinoviruses and help clear an infection quickly, while accelerating the production of antibodies against the infecting strain.
- Apollo said vaccination produced rhinovirus-specific cellular immunity and seroconversion. T cells responded to peptide pools representing RV-A, RV-B and RV-C, the company reported.
Reality check: The readout shows cross-reactive immune recognition, not protection against infection or COPD exacerbations. The company did not disclose response rates, dose-response data or the magnitude and durability of immunity. Participants were also healthy. Apollo will need to show that older people with COPD generate a useful response and, ultimately, that vaccination reduces clinically meaningful exacerbations.
The competitive landscape: Human trials directly targeting rhinovirus-associated COPD exacerbations remain scarce.
- Vapendavir: Altesa Biosciences’ oral rhinovirus capsid inhibitor produced encouraging results in a Phase 2a controlled-infection study. Of 52 people with moderate COPD enrolled, 40 developed symptoms after RV-A16 challenge and were randomized. Vapendavir improved symptom and quality-of-life measures and shortened median viral shedding from 11 to five days, although spirometry tests measuring airflow and lung function showed no significant difference.
- SNG001: Synairgen’s inhaled interferon beta-1a is designed to restore the lung’s broad antiviral defenses rather than attack rhinovirus directly. In a Phase 2 study, 109 people with COPD and a confirmed respiratory viral infection received SNG001 or placebo. Clinical efficacy differences were minimal overall, but a post-hoc rhinovirus subgroup showed faster viral clearance: 20% of SNG001 recipients still had detectable rhinovirus on Day 7, compared with 89.5% on placebo.
- GSK3923868: GSK’s inhaled drug inhibits PI4K-beta, a human enzyme rhinoviruses use to replicate. A 12-person Phase 1 safety and pharmacokinetic study in stable COPD has been completed. GSK also completed a 48-person Phase 1b rhinovirus-challenge trial in mild asthma, but efficacy results have not been publicly posted. The asset isn’t listed on GSK’s 1 pipeline at the moment.
Apollo’s unusual model: Founded in 2016, Apollo began as a joint venture between the universities of Cambridge, University College London and Imperial College London, and pharma groups AstraZeneca, GSK and Johnson & Johnson.
- Apollo became an independent portfolio biopharma in 2021 and now has research partnerships with six UK institutions, also including Oxford, King’s College London and the Institute of Cancer Research. Instead of building a separate startup around each academic discovery, its central drug-development team selects and advances multiple programs inside one company. It supplements that pipeline by acquiring or licensing outside clinical assets.
What’s next: Apollo plans to start a placebo-controlled Phase 2 trial in people with COPD in the first half of 2027. That study will provide the first meaningful test of whether APL-10456’s broad immune responses translate into fewer exacerbations.
